Bile duct cancer combo therapy trial ends early with just one patient
NCT ID NCT06739252
First seen Jan 29, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study aimed to see if giving chemotherapy directly into the liver artery along with immunotherapy drugs before and after surgery could improve outcomes for people with high-risk bile duct cancer. Only one person enrolled before the study was stopped early. The approach was designed to shrink tumors before surgery and prevent return afterward, but results are not available due to early termination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peing University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.